The top analyst upgrades, downgrades and other research calls from Tuesday include AngioDynamics, Commercial Metals, Eldorado Resorts, Gamestop, Marvell Technology, Spotify and U.S. Steel.
The top analyst upgrades, downgrades and other research calls from Wednesday include Callaway Golf, Capital One, Sarepta Therapeutics, Tesla, UnitedHealth and Wayfair.
The top analyst upgrades, downgrades and initiations include ConocoPhillips, Goodyear Tire, Humana, Lululemon Athletica and Range Resources.
The top analyst upgrades, downgrades and initiations seen on Thursday include Biogen, Goldcorp, GoPro, Oracle, Sirius XM, Tyson Foods and Ciena.
The top analyst upgrades, downgrades and initiations seen om Monday include Apple, Dow Chemical, GoPro, Netflix, Snap, FedEx and MetLife.
The three biotech stocks featured here are rated Outperform at Wedbush and have at least 100% potential upside to the posted price targets.
A new report from Wedbush focuses on upcoming catalysts for biotech stocks in the firm's coverage universe. These four have monster potential upside to the posted price targets.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Abercrombie & Fitch, Apple, Best Buy, Cisco Systems, Procter & Gamble, Synchrony Financial and U.S. Steel.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include ADM, General Mills, Home Depot, Microsoft, 3D Systems and Western Digital.
April 28, 2016: Here are four stocks trading with relatively heavy volume among 18 equities making new 52-week lows in Thursday’s session. NYSE decliners led advancers by about 2 to 1 while…
Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it still sees significant upside ahead.
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
In a new research report, the boutique firm Leerink highlights 10 top biotech names that are strong candidates for a partnership or acquisition. Any of these picks may be a great addition…
Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms Monday, December 23, 2013.
